


## PAR4 antagonist 3

Cat. No.:	HY-162408
Molecular Formula:	C <sub>22</sub> H <sub>16</sub> FN <sub>3</sub> O <sub>5</sub> S
Molecular Weight:	453.44
Target:	Protease Activated Receptor (PAR)
Pathway:	GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	PAR4 antagonist 3 (Compound 36) is a selective antagonist for protease activated receptor 4 (PAR4). PAR4 antagonist 3 exhibits antiplatelet efficacy with IC <sub>50</sub> of 26.1 nM. PAR4 antagonist 3 improves metabolic stability in human liver microsomes with T <sub>1/2</sub> of 97.6 min <sup>[1]</sup> .																																
<b>In Vitro</b>	PAR4 antagonist 3 (4 μM) exhibits antagonistic effect on GPVI, that inhibits collagen-induced platelet aggregation signaling pathway <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.																																
<b>In Vivo</b>	<p>PAR4 antagonist 3 (3-12 mg/kg, po, single dose) suppresses the bleeding time, exhibits no impact on the coagulation system in C57BL/J6 mice tail cutting model<sup>[1]</sup>.</p> <p>PAR4 antagonist 3 (2 mg/kg, iv or 12 mg/kg, po) shows pharmacokinetics profiles as shown in table below:</p> <p>Pharmacokinetic Analysis of PAR4 antagonist 3 in ICR mice<sup>[1]</sup></p> <table border="1"> <thead> <tr> <th>Route</th> <th>Dose (mg/kg)</th> <th>T<sub>1/2</sub> (h)</th> <th>T<sub>max</sub> (h)</th> <th>C<sub>max</sub> (ng/mL)</th> <th>AUC<sub>0→t</sub> (ng·h/mL)</th> <th>Cl (mL/h·kg)</th> <th>F (%)</th> </tr> </thead> <tbody> <tr> <td>i.v.</td> <td>2 mg/kg</td> <td>11.3</td> <td>-</td> <td>-</td> <td>1250</td> <td>1428</td> <td>-</td> </tr> <tr> <td>p.o.</td> <td>12 mg/kg</td> <td>7.32</td> <td>1.67</td> <td>325</td> <td>3460</td> <td>-</td> <td>45</td> </tr> </tbody> </table> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>C57BL/J6 mice tail cutting model<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>3-12 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>po, single dose</td> </tr> <tr> <td>Result:</td> <td>Suppressed the bleeding time.</td> </tr> </table>	Route	Dose (mg/kg)	T <sub>1/2</sub> (h)	T <sub>max</sub> (h)	C <sub>max</sub> (ng/mL)	AUC <sub>0→t</sub> (ng·h/mL)	Cl (mL/h·kg)	F (%)	i.v.	2 mg/kg	11.3	-	-	1250	1428	-	p.o.	12 mg/kg	7.32	1.67	325	3460	-	45	Animal Model:	C57BL/J6 mice tail cutting model <sup>[1]</sup>	Dosage:	3-12 mg/kg	Administration:	po, single dose	Result:	Suppressed the bleeding time.
Route	Dose (mg/kg)	T <sub>1/2</sub> (h)	T <sub>max</sub> (h)	C <sub>max</sub> (ng/mL)	AUC <sub>0→t</sub> (ng·h/mL)	Cl (mL/h·kg)	F (%)																										
i.v.	2 mg/kg	11.3	-	-	1250	1428	-																										
p.o.	12 mg/kg	7.32	1.67	325	3460	-	45																										
Animal Model:	C57BL/J6 mice tail cutting model <sup>[1]</sup>																																
Dosage:	3-12 mg/kg																																
Administration:	po, single dose																																
Result:	Suppressed the bleeding time.																																

---

## REFERENCES

---

[1]. Chen P, et al., Discovery of 2,3-Dihydro[1,4]dioxino[2,3-g]benzofuran Derivatives as Protease Activated Receptor 4 (PAR4) Antagonists with Potent Antiplatelet Aggregation Activity and Low Bleeding Tendency. J Med Chem. 2024 Apr 11;67(7):5502-5537.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA